Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
April 28 2022 - 4:05PM
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company
focused on developing both restorative therapeutics and pan-caspase
and caspase selective inhibitors focused on treatments for
infectious and inflammatory diseases, today announced that
Histogen’s financial results for the first quarter ended March 31,
2022 will be released after the close of market on Thursday, May
12, 2022.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics
company focused on developing both potential first-in-class
restorative therapeutics that ignite the body’s natural process to
repair and maintain healthy biological function as well as a
pipeline of clinical and preclinical small molecule pan-caspase and
caspase selective inhibitors focused on treatments for infectious
and inflammatory diseases. Under our biologics technology platform,
our product candidates in development are HST-003, a treatment for
joint cartilage repair, and HST-004, a treatment for spinal disc
repair. In addition, within our small molecule pipeline, our
product candidates include emricasan, CTS-2090 and CTS-2096.
Currently, emricasan is being developed jointly with our
collaboration partner, Amerimmune, for the treatment of COVID-19,
and we are evaluating the use of emricasan for other infectious
diseases including the treatment of MRSA. We also have preclinical
product candidates, CTS-2090 and CTS-2096, novel, potent, orally
bioavailable, and highly selective small molecule inhibitors of
caspase-1 designed for the treatment of certain inflammatory
diseases. For more information, please
visit www.histogen.com.
CONTACT:
Susan A. KnudsonExecutive Vice
President & CFOHistogen Inc.ir@histogen.com
Histogen (NASDAQ:HSTO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Histogen (NASDAQ:HSTO)
Historical Stock Chart
From Sep 2023 to Sep 2024